医药生物

Junshi Biosciences' Toripalimab Combined with RemeGen's RC48 Approved for New Indication

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

161726

159859

160635

512290

399441

<p>Benefiting from the recovery of industry prosperity and favorable policies, more than 50 A-share biomedicine companies are expected to achieve profitability by 2025. According to Wind data, as of January 26, over 90 companies have released performance forecasts, among which 53 companies expect to be profitable, 14 companies expect to double their net profits, 10 companies expect to turn losses into profits, and 14 companies expect to reduce their losses year-on-year</p>

Wallstreetcn

China Merchants CNI BIOMEDICINE Index Fund-A

Tianhong CNI BIOMEDICINE ETF

Penghua CSI Health Care Index Fund(LOF)-A

Guotai CSI Bio-medicine ETF

CNI BIOMEDICINE

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025

医药生物(000808.SH)

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025